UK Fabry disease is among the most comprehensively characterised rare diseases in Europe — an NHS specialist-centre network, a 600-patient longitudinal outcomes registry, and free NHS genetic cascade testing driving high diagnosis rates.
Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A (GLA) deficiency. An estimated 800 patients are diagnosed in the UK, managed through NHS Highly Specialised Services at lysosomal storage disorder centres in London (GSTT/King's), Manchester, Cambridge (Addenbrooke's), Birmingham, Edinburgh, and Belfast. The UK Fabry Outcome Survey (UK FOS), a Sanofi-sponsored longitudinal registry, tracks roughly 600 UK patients — giving the UK one of the best-characterised Fabry populations globally, with data showing proteinuria in 55% of males and 35% of females at diagnosis, left ventricular hypertrophy in 60% of males, and neuropathic pain (acroparesthesia) reported by 85% of patients at some point in their disease course.
The NHS Genomic Medicine Service offers free GLA gene testing for probands and first-degree relatives, with genetic counselling available before and after testing. This drives a family-cascade yield the UK FOS estimates at 3–4 additional diagnosed relatives per index case, consistent with international data, and gives the UK the highest per-capita Fabry diagnosis rate in Europe. Both treatment pathways are NHS-commissioned: enzyme replacement therapy (agalsidase beta/Fabrazyme, which has never been formally appraised by NICE and is commissioned via clinical policy) for all patients, and oral migalastat (Galafold, NICE HST4, with a patient access scheme) for the roughly 35–50% of patients whose GLA mutation is 'amenable' — confirmed via an HEK cell assay available at the NHS genetics labs in GSTT, Manchester, and Birmingham. On treatment, UK FOS data shows renal function stabilisation in around 70% of patients and cardiac LVH regression in about 40% of responders.
UK Fabry disease manifestations at diagnosis — UK Fabry Outcome Survey
| Manifestation | Males (%) | Females (%) | Median Age at Diagnosis | On-Treatment Outcome |
|---|---|---|---|---|
| Proteinuria | 55% | 35% | 33 (M) / 38 (F) | Renal stabilisation in ~70% on ERT/migalastat |
| Left ventricular hypertrophy | 60% | Not separately reported | 33 (M) / 38 (F) | LVH regression in ~40% of responders |
| White matter lesions (MRI) | 50% | Not separately reported | 33 (M) / 38 (F) | Tracked longitudinally in UK FOS |
| Neuropathic pain (acroparesthesia) | 85% (combined) | 85% (combined) | 33 (M) / 38 (F) | Frequently first presenting symptom |
Sources: UK Fabry Outcome Survey 2023; NHS clinical commissioning policy (agalsidase beta); NICE HST4 evidence summary (migalastat, 22 February 2017); NHS England lysosomal storage disorder service specification.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Six NHS LSD centre network
- UK FOS registry scope and longitudinal outcomes data
- organ-manifestation burden by sex at diagnosis
Delivers
- NHS clinical-policy ERT vs NICE HST4 migalastat eligibility split
- HEK cell assay access and amenability testing
- NHS commissioning and patient access scheme status for both pathways
Delivers
- NHS GMS cascade testing pathway and yield
- biochemical vs genetic testing by sex
- the per-capita diagnosis-rate advantage vs other European markets
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How alpha-galactosidase A (GLA) deficiency, X-linked, drives multi-organ glycosphingolipid accumulation in Fabry disease
- Why males and females present differently, with proteinuria in 55% of males versus 35% of females at diagnosis
- The six NHS lysosomal storage disorder centres managing an estimated 800 diagnosed UK patients: GSTT/King's, Manchester, Addenbrooke's, Birmingham, Edinburgh, and Belfast
- How the UK Fabry Outcome Survey's roughly 600-patient longitudinal cohort makes UK data among the best-characterised in Europe
- How free NHS GMS GLA gene testing for probands and first-degree relatives drives 3-4 additional diagnoses per index case
- Why this cascade yield gives the UK the highest per-capita Fabry diagnosis rate in Europe
- Organ manifestation burden at diagnosis: left ventricular hypertrophy in 60% of males and neuropathic pain in 85% of all patients
- On-treatment outcomes: renal function stabilisation in around 70% of patients and cardiac LVH regression in about 40% of responders
- Why agalsidase beta has never been formally appraised by NICE and is instead commissioned via NHS clinical policy for all patients
- How the roughly 35-50% of patients with an 'amenable' GLA mutation, confirmed via HEK cell assay, qualify for oral migalastat under NICE HST4
- What the roughly 30% of patients without renal stabilisation and 60% without LVH regression mean for a next-generation ERT case
- How the amenable-mutation split defines the addressable population for a pipeline agent targeting suboptimal ERT or migalastat responders
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
UK Fabry disease landscape is built from primary NHS and NICE sources, including NHS clinical commissioning policy for agalsidase beta, NICE's Highly Specialised Technology appraisal HST4 for migalastat, NHS England lysosomal storage disorder service specification, and NHS Genomic Medicine Service GLA panel documentation, together with UK Fabry Outcome Survey registry data, not secondary summaries or unverified estimates.
Key sources: NHS clinical commissioning policy (agalsidase beta); NICE HST4 evidence summary (migalastat, 2017); UK Fabry Outcome Survey (UK FOS) 2023; NHS England LSD service specification; NHS GMS GLA cascade testing programme documentation.
- UK Fabry patient estimate and centre network verified against NHS clinical policy, NICE HST4, and NHS England LSD service specification
- Family-cascade yield verified against UK FOS cascade data
- Disease-burden statistics at diagnosis verified against UK Fabry Outcome Survey 2023
- ERT and migalastat eligibility criteria verified against NHS clinical commissioning policy and the NICE HST4 evidence summary
Frequently asked questions
Commission this assessment
AXLRx UK Fabry Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the UK Fabry disease patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.